title: Tranexamic acid for cesarean section: a double-blind, placebo-controlled, randomized clinical trial.
abstract: OBJECTIVE
  To assess the efficacy and safety of an intravenous formulation of tranexamic acid to reduce intrapartum and postpartum bleeding in patients giving birth by cesarean section.
  
  
  METHODS
  Healthy women with normal pregnancies, at any gestational age, that we performed ceaserean section. Two hundred and twenty-three patients with cesarean section, were enrolled in a double-blind, placebo-controlled study. Tranexamic acid of 20 cc and a 20 cc 5 % dextrose solution was intravenously injected to the patients; both the study group (n = 101) and the control group (n = 122) 10 min before the start of cesarean section. We measured volume of blood loss in postoperative periods, decrease in hemoglobin and hematocrit levels after cesarean section. The mean follow up was 2 weeks after the operation.
  
  
  RESULTS
  Tranexamic acid reduced intraoperative and postoperative blood loss. We did not observe any complications caused by TA such as venous thromboembolism, gastrointestinal problems and hypersensitivity.
  
  
  CONCLUSIONS
  This study confirms that tranexamic acid is effective in reducing intrapartum and postpartum bleeding in patients giving birth by cesarean section. Although some obstetricians are still worried about its thrombosis risk, our study shows that it can be used safely in aforementioned patients.
authors.affiliation: Department of Obstetrics and Gynecology, Batman Women Health And Children's Hospital, Batman, Turkey.
authors.forename: Mehmet B
authors.initials: MB
authors.lastname: Sentürk
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Cakmak
authors.forename: Gazi
authors.initials: G
authors.lastname: Yildiz
authors.forename: Pınar
authors.initials: P
authors.lastname: Yildiz
mesh_terms: D000328:Adult; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002585:Cesarean Section / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006403:Hematologic Tests; D006801:Humans; D006473:Postpartum Hemorrhage / Q000517:prevention & control*; D011247:Pregnancy; D014148:Tranexamic Acid / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid